arrow_back Back to App

End Drug Shortages: Faster Warnings, Better Access

This act aims to improve drug availability by requiring earlier notification of potential shortages, including sudden surges in demand. This means citizens can expect key medications to be more readily available, and the healthcare system will be better prepared for potential supply issues. These changes are designed to enhance security and certainty in accessing essential medicines.
Key points
Drug manufacturers must now report not only production interruptions but also sudden surges in demand that could lead to shortages.
Information about shortages will be provided more quickly, allowing for better planning and prevention of drug unavailability in pharmacies and hospitals.
The definition of a drug shortage has been expanded to include situations where demand exceeds supply, helping to identify problems early.
The act also requires public disclosure of information on bulk drug substances, increasing transparency and aiding supply chain monitoring.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_10239
Sponsor: Rep. Spanberger, Abigail Davis [D-VA-7]
Process start date: 2024-11-21
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

End Drug Shortages Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_10239.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2024-11-21.

What are the main provisions?

Key points include:

  • Drug manufacturers must now report not only production interruptions but also sudden surges in demand that could lead to shortages.
  • Information about shortages will be provided more quickly, allowing for better planning and prevention of drug unavailability in pharmacies and hospitals.
  • The definition of a drug shortage has been expanded to include situations where demand exceeds supply, helping to identify problems early.
  • The act also requires public disclosure of information on bulk drug substances, increasing transparency and aiding supply chain monitoring.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Spanberger, Abigail Davis [D-VA-7].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-24.

CATEGORIES

Health